GlassScriptPhysician profile
Harry J Doyle
NPI 1689801730
$4,401.75
in general payments reported to CMS, 2019-2025
34 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,023 · 2022: $650 · 2023: $488 · 2024: $1,041 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,728.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,230.85 | 2021-2025 | |
| Novo Nordisk INC | $586.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $430.10 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $220.81 | 2023-2025 | Voquezna |
| Pfizer INC. | $194.93 | 2023-2025 | |
| Lilly USA, LLC | $153.88 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $148.49 | 2021-2024 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $121.41 | 2022-2025 | |
| Glaxosmithkline, LLC. | $118.48 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $107.81 | 2021-2022 | |
| Inspire Medical Systems, INC. | $104.15 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $95.36 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $95.25 | 2021-2025 | |
| Abiomed | $91.12 | 2024-2025 | Impella |
| Amgen INC. | $70.09 | 2023-2025 | Repatha, Otezla, Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $66.99 | 2025 | Keveyis |
| Daiichi Sankyo INC. | $60.71 | 2021 | |
| Exact Sciences Corporation | $54.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $44.26 | 2021-2022 | |
| Mylan Specialty L.P. | $41.97 | 2021 | |
| Shield Therapeutics INC | $36.55 | 2024 | |
| Antares Pharma, INC. | $35.18 | 2024-2025 | Xyosted |
| Abbott Laboratories | $33.69 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.21 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $33.20 | 2021 | |
| Verity Pharmaceuticals INC. | $31.83 | 2024-2025 | Tlando |
| Idorsia Pharmaceuticals US INC | $29.02 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $28.85 | 2025 | Gemtesa |
| Eisai INC. | $25.22 | 2021 | |
| Ironwood Pharmaceuticals, INC | $19.03 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.14 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.12 | 2024 | |
| Halozyme INC | $13.68 | 2023 | |
| Corcept Therapeutics | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.